March 2016 Issue of The Translational Scientist

Want a lightning-fast tour of the latest issue? Take a look at our new video sneak preview.

“Extraordinary” results from a T-cell therapy trial offer hope to leukemia patients – and to researchers toiling in unfashionable fields.

Another study supports potential surgical transmission of amyloid beta plaques – but the discussion is far from closed

How can we get drugs to the liver to treat its dysfunction, without making it worse?

French physicists have developed a thermal imaging technique that maps heat across a single cell

What can Drosophila eyes tell us about the origins of cancer?

Researchers can control aggression in mice by turning on specific neurons – but what are the implications for human rage?

What do we know so far?

A gene therapy approach for hemophilia-causing Factor VII deficiency shows early promise

How do birds transmit potentially fatal fungal infection to humans without being infected themselves?

Open innovation is more than just the latest pharma industry buzzword. Done right, it can help overcome funding challenges and accelerate discovery across the board.

There is an assumption that doctors and business don’t mix. But I believe physicians are ideally placed to bring new clinical innovations from a bright idea to a brand new product.

The Ebola epidemic spurred a tremendous amount of R&D in search of vaccines and treatments – and yet it was a relatively low impact global emergency compared with malaria.

Hundreds of potential drug targets have been discovered by researchers mapping pain pathways, but clinical trials have proved unsuccessful in most cases. Can we pick our way through the translational maze to find much-needed new analgesics?

Basic and clinical researchers must join forces to fight pain.

Chronic pain is the most prevalent and expensive public health problem in the developed world, but as a society we consistently fail to recognize the scale of the public health issue.

Does pain in early childhood have a profound impact later in life?

How and what we measure in animal studies of pain has huge implications for clinical translation.

Shotgun sequencing is a powerful tool in microbial genomics, but viral genomes have proven tough to crack.

A new technique allows scientists to see conformational changes caused by ligand binding in real time, opening up new screening options for drug discovery.

The XChem facility offers drug discovery scientists streamlined, highly sensitive fragment screening, by harnessing the power of synchrotron light.

Developing a dengue vaccine has been like a 20-year game of Snakes and Ladders – but in this game, there are four billion winners, as the prize could help protect half the world’s population.

As the judges deliberate over this year's winner, we speak with three of the top-placed entrants from the 2015 Humanity in Science Award.

Sitting Down With…John Doench, Associate Director, Genetic Perturbation Platform, Broad Institute, Cambridge, MA, USA.